On the other hand, NAFLD, especially its more severe forms, may aggravate insulin resistance, predispose to dyslipidemia and enhance synthesis of pro-inflammatory, pro-coagulant, pro-oxidant and pro-fibrogenic mediators (CRP, IL-6, fibrinogen, plasminogen activator inhibitor 1 and tumor growth factor beta) in the liver [6, 19, 20, 153]. This evidence concerns the gene CRP and metabolic dysfunction-associated steatotic liver disease.